Live feed
Filing
SCHEDULE 13D/A
SCHEDULE 13D/A0001104659-25-102608·Fairmount Funds Management LLC
Schedule 13D ownership disclosure
Viridian Therapeutics Inc
Common Stock, $0.01 par value · CUSIP: 92790C104
Event date: 2025-10-23
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Fairmount Funds Management LLCReported CIK 0001802528
Shares: 16,025,330.00 · Class: 15.14%
- Fairmount Healthcare Fund II GP LLCReported CIK 0001830382
Shares: 16,025,330.00 · Class: 15.14%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001104659-25-102608
- Form type
- SCHEDULE 13D/A
- Filer
- Fairmount Funds Management LLC
- CIK
- CIK 1802528
- Filed
- Oct 27, 2025
- Reporting period
- Oct 23, 2025
- Description
- Schedule 13D beneficial ownership